- Conditions
- Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
- Interventions
- Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Migraine
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Migraine
- Interventions
- Emgality 120 MG in 1 ML Prefilled Syringe
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 80
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 72 more
- Conditions
- Chronic Cluster Headache
- Interventions
- Galcanezumab 300 mg, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Santa Monica, California • Stanford, California + 10 more
- Conditions
- Migraine
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
- Conditions
- Healthy
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Migraine Disorders
- Interventions
- LY2951742, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Episodic Cluster Headache, Chronic Cluster Headache
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 8 more
- Conditions
- Chronic Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Apple Valley, California • Los Angeles, California + 44 more
- Conditions
- Healthy
- Interventions
- Galcanezumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
- Conditions
- Migraine
- Interventions
- Ubrogepant, Erenumab, Galcanezumab
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Springfield, Missouri • West Bend, Wisconsin
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug · Other
- Lead sponsor
- Diamond Headache Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Episodic Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
- Conditions
- Migraine, Episodic Migraine, Chronic Migraine, Headache
- Interventions
- CGRP antibody or gepant
- Drug
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Migraine Headache
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Encino, California + 34 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- LY2951742, Placebo- oral, Placebo - SC, Celecoxib
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Anaheim, California • San Diego, California + 31 more
- Conditions
- Migraine Headache
- Interventions
- LY2951742, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 37
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more
- Conditions
- Migraine
- Interventions
- Eptinezumab, Erenumab, Onabotulinumtoxin-A, Fremanezumab, Galcanezumab
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Stamford, Connecticut • Palmetto Bay, Florida + 7 more
- Conditions
- Trigeminal Neuralgia, Glossopharyngeal Neuralgia
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Post-Traumatic Headache
- Interventions
- Galcanezumab-Gnlm
- Drug
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • San Diego, California • Ocoee, Florida + 15 more
- Conditions
- Vestibular Migraine
- Interventions
- Galcanezumab Prefilled Syringe, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California